(NASDAQ: ARDX) Ardelyx's forecast annual revenue growth rate of 30.1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.04%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.47%.
Ardelyx's revenue in 2026 is $450,894,000.On average, 14 Wall Street analysts forecast ARDX's revenue for 2026 to be $137,643,739,146, with the lowest ARDX revenue forecast at $128,207,005,794, and the highest ARDX revenue forecast at $149,584,807,596. On average, 14 Wall Street analysts forecast ARDX's revenue for 2027 to be $187,977,136,814, with the lowest ARDX revenue forecast at $170,384,494,231, and the highest ARDX revenue forecast at $201,468,151,962.
In 2028, ARDX is forecast to generate $249,935,134,716 in revenue, with the lowest revenue forecast at $208,826,660,963 and the highest revenue forecast at $285,319,769,940.